2024 Board Meetings

November 25, 2024

The Maryland Prescription Drug Affordability Board invites you to attend the November Board Meeting, scheduled for Monday, November 25, 2024 at 2:00 pm. Part of the meeting may be conducted in closed session. Because the meeting will be livestreamed here​, registration is not required. You may also attend in person at the following address:


Miller Senate Building, William Amoss Room, 4th Floor

11 Bladen Street

Annapolis, MD 21401


PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Wednesday, November 20, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation and provide additional details.


WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please include in the subject line: November Board Meeting Comments. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, November 20, 2024.


AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.


Written Comments Received:

October 28, 2024- Ad-Hoc Meeting

The Maryland Prescription Drug Affordability Board invites you to attend the October Board Meeting, scheduled for Monday, October 28, 2024 at 2:00 pm. The meeting will be held remotely. Part of the meeting may be conducted in closed session. Please ​register for the meeting he​re. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting.

PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Wednesday, October 23, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.

WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please submit any written comments, concerning this agenda no later than the close of business on Monday, Wednesday, October 23, 2024. Please utilize the subject line “October Board Comments.

AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.


  • Comments Received for the 10/28/2024 Meeting

September 10, 2024

The Maryland Prescription Drug Affordability Board invites you to attend the September Board Meeting, scheduled for Tuesday, September 10, 2024 at 2:00 pm. The meeting will be held remotely. Part of the meeting may be conducted in closed session. Please ​register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting.

Please note that the September 23, 2024 scheduled PDAB meeting has been CANCELED and rescheduled for September 10, 2024. 

PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Thursday, September 5, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.

WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please submit any written comments, concerning this agenda no later than the close of business on Monday, Thursday, September 5, 2024. Please utilize the subject line “Sept Board Comments.

AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.



July 22, 2024
The Maryland Prescription Drug Affordability Board invites you to attend the July Board Meeting, scheduled for Monday, July 22, 2024, at 2:00 pm. Part of the meeting may be conducted in closed session. Because the meeting will be livestreamed here​, registration is not required. You may also attend in person at the following address:

Miller Senate Building, William Amoss Room, 4th Floor
11 Bladen Street
Annapolis, MD 21401

PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Wednesday, July 17, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation and provide additional details.

WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please include in the subject line: July Board Meeting Comments. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, July 17, 2024.

AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
The following entities provided written comment in the above packet:​
  • ​MedChi
  • Manva Singla, M.D., F.A.A.P., F.A.A.A.A.I., F.A.C.A.A.A.I., Allergy Asthma Specialists of Maryland​​​
  • PhRMA
  • Boehringer Ingelheim
  • Johnson and Johnson


May 20, 2024
The Maryland Prescription Drug Affordability Board invites you to attend the May Board Meeting, scheduled for Monday, May 20, 2024, at 2:00 pm. Part of the meeting may be conducted in closed session. Because the meeting will be livestreamed here​, registration is not required. You may also attend in person at the following address:

Miller Senate Building, William Amoss Room, 4th Floor
11 Bladen Street
Annapolis, MD 21401

PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Wednesday, May 15, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation and provide additional details.

WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please include in the subject line: May Board Meeting Comments. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, May 15, 2024.

AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.

Comments Received for May 20th Board Meeting:
The following entities provided written comment in the above packet:
  • Melissa Lynn Abrams, MD, FAAD

  • American Partnership for Eosinophilic Disorders

  • Oluyomi Amoye- Consumer (Verifying this is ok to post)​

  • AstraZeneca

  • Baltimore-Washington Conference of the United Methodist Church

  • Committee to Protect Health Care

  • Delaware-Maryland Synod

  • Amit Mickey Dhir, MSN, MBA, AGPCNP-C, AAHIVS

  • Families USA- The Voice for Healthcare Consumers

  • Gilead

  • HIV+HEP Policy Institute

  • Infectious Disease Care Center

  • Susan Lovelace, MS, CRNP

  • Partnership to Improve Patient Care

  • Progressive Maryland

  • Regeneron

  • Value of Care Coalition

  • Dr. Chikoti Wheat

  • Brittany Yerkes, MS PA-C, AAHIVM


Comments Received for May 20th Board Meeting after deadline and not included in the packet above:


March 25, 2024

The Maryland Prescription Drug Affordability Board invites you to attend the March Board Meeting, scheduled for Monday, March 25, 2024, at 2:00 pm, remotely. Part of the meeting may be conducted in closed session. Please ​register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting

PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Wednesday, March 20, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail

WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, March 20, 2024.

AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.

  • Written Public Comment
  • The following entities provided written comment in the above attachment:
    1. Ai Arthritis
    2. Chronic Disease Coalition
    3. Committee to Protect Health Care
    4. Community Access National Network
    5. Karoll Cortez, MD- GBMC
    6. Amit “Mickey" Dhir, HIV Specialist
    7. Dr. Paul Eder
    8. Gilead
    9. HIV + HEP Policy Institute
    10. Infectious Disease Care Center
    11. Maryland Citizens Health Initiative, Maryland HealthCare for All Coalition
    12. Maryland Commission on LGBTQIA+ Affair
    13. Anya Mitchell
    14. Park West Health System
    15. Sanofi
    16. Sinai Hospital of Baltimore

  • Comment Received after Deadline: Dr. Catanzaro
  • Global Coalition on Aging
  • HealthHIV


January 29, 2024

The Maryland Prescription Drug Affordability Board invites you to attend the January Board Meeting, scheduled for Monday, January 29, 2024, at 2:00 pm, remotely. Part of the meeting may be conducted in closed session. Please ​register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting

PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Wednesday, January 24, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail

WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, January 24, 2024.

AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.


Written Comments: